OTLK is trading at $1.61 (-5.24%) today as the stock gives back part of its recent gains following the FDA's acceptance of its resubmitted BLA.
- The FDA has set a PDUFA goal date of July 29, 2026, for Lytenava, which remains the primary catalyst for the stock's recent volatility.
- The downward move appears to be company-specific profit-taking following the recent surge, as broader markets are currently trading higher.